Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc (LXEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 761,984
  • Shares Outstanding, K 72,987
  • Annual Sales, $ 0 K
  • Annual Income, $ -98,330 K
  • EBIT $ -114 M
  • EBITDA $ -113 M
  • 60-Month Beta 1.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.83

Options Overview Details

View History
  • Implied Volatility 234.72% (+45.97%)
  • Historical Volatility 64.99%
  • IV Percentile 52%
  • IV Rank 25.18%
  • IV High 695.76% on 04/17/25
  • IV Low 79.58% on 08/18/25
  • Expected Move (DTE 23) 0.85 (8.05%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 23
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 1,727
  • Open Int (30-Day) 2,574
  • Expected Range 9.71 to 11.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.32
  • Number of Estimates 6
  • High Estimate -0.26
  • Low Estimate -0.38
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +58.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.30 +27.23%
on 12/03/25
10.99 -3.91%
on 12/23/25
+0.57 (+5.71%)
since 11/24/25
3-Month
6.30 +67.62%
on 09/25/25
10.99 -3.91%
on 12/23/25
+4.02 (+61.47%)
since 09/24/25
52-Week
1.45 +628.28%
on 04/07/25
10.99 -3.91%
on 12/23/25
+4.21 (+66.30%)
since 12/24/24

Most Recent Stories

More News
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc . (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from Oppenheimer

Oppenheimer analyst Leland Gershell maintained a Buy rating on Lexeo Therapeutics, Inc. today and set a price target of $20.00. The company’s shares closed yesterday at $8.34.Elevate Your Investing Strategy:...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Advances FDA Discussions for LX2006

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lexeo Therapeutics,...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia...

LXEO : 10.56 (+1.15%)

Business Summary

Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.

See More

Key Turning Points

3rd Resistance Point 11.52
2nd Resistance Point 11.25
1st Resistance Point 10.85
Last Price 10.56
1st Support Level 10.18
2nd Support Level 9.91
3rd Support Level 9.51

See More

52-Week High 10.99
Last Price 10.56
Fibonacci 61.8% 7.35
Fibonacci 50% 6.22
Fibonacci 38.2% 5.09
52-Week Low 1.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar